{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:05:05Z","timestamp":1780315505447,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002648","name":"Catholic University of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2026.01.025","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:27:40Z","timestamp":1768868860000},"page":"588.e1-588.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tandem Conditioning-Based Myeloablative Hematopoietic Stem Cell Transplantation for Pediatric Patients with Refractory Myeloid Leukemias"],"prefix":"10.1016","volume":"32","author":[{"given":"Jae Won","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suejung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-3067","authenticated-orcid":false,"given":"Seongkoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-0287","authenticated-orcid":false,"given":"Jae Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-390X","authenticated-orcid":false,"given":"Nack-Gyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-695X","authenticated-orcid":false,"given":"Bin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtct.2026.01.025_bib0001","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2017.3","article-title":"Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience","volume":"52","author":"O'Hare","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.01.025_bib0002","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41409-019-0461-0","article-title":"Hematopoietic stem cell transplantation in children with refractory acute myeloid leukemia","volume":"54","author":"Okamoto","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1016\/j.jtct.2026.01.025_bib0003","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.01.025_bib0004","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.01.025_bib0005","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3324\/haematol.2018.203869","article-title":"Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience","volume":"104","author":"Ram","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2026.01.025_bib0006","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-019-0584-8","article-title":"Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial","volume":"34","author":"Sauer","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2026.01.025_bib0007","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.bbmt.2009.08.014","article-title":"Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study","volume":"15","author":"Sisler","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.01.025_bib0008","doi-asserted-by":"crossref","first-page":"915.e1","DOI":"10.1016\/j.jtct.2021.07.018","article-title":"FLAMSA-busulfan-melphalan as a sequential conditioning regimen in HLA-matched or haploidentical hematopoietic stem cell transplantation for high-risk myeloid diseases","volume":"27","author":"Jondreville","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.01.025_bib0009","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jtct.2022.06.005","article-title":"Hematopoietic cell transplantation in the treatment of pediatric acute myelogenous leukemia and myelodysplastic syndromes: guidelines from the American Society of Transplantation and Cellular Therapy","volume":"28","author":"Tarlock","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.025_bib0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.025_bib0011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/petr.12073","article-title":"Reduced-dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia","volume":"17","author":"Chung","year":"2013","journal-title":"Pediatr Transpl"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.025_bib0012","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/bmt.2014.202","article-title":"Impact of CD34+ cell dose in children who receive unrelated PBSCT with in vivo T-cell depletion for hematologic malignancies","volume":"50","author":"Lee","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"9823","key":"10.1016\/j.jtct.2026.01.025_bib0013","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jtct.2026.01.025_bib0014","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.31557\/APJCP.2021.22.5.1639","article-title":"Adverse effects of busulfan plus cyclophosphamide versus busulfan plus fludarabine as conditioning regimens for allogeneic bone marrow transplantation","volume":"22","author":"Mehdizadeh","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"10.1016\/j.jtct.2026.01.025_bib0015","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/pbc.25437","article-title":"Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3\/ITD acute myeloid leukemia","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.025_bib0016","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1097\/MPH.0000000000000672","article-title":"Sorafenib therapy for pediatric acute myeloid leukemia with FMS-like tyrosine kinase 3-internal tandem duplication mutations: 2 case reports","volume":"39","author":"Osone","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.01.025_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26664","article-title":"Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups","volume":"64","author":"Creutzig","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2026.01.025_bib0018","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood.2020007897","article-title":"Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia","volume":"137","author":"Xiao","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.025_bib0019","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jha2.856","article-title":"Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent\/young adult patients","volume":"5","author":"Pemmaraju","year":"2024","journal-title":"EJHaem"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:08:37Z","timestamp":1780312117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S266663672600059X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tandem Conditioning-Based Myeloablative Hematopoietic Stem Cell Transplantation for Pediatric Patients with Refractory Myeloid Leukemias","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}